Zomedica Reports Record Third-Quarter Revenue of $9.9 Million, Up 22%

Zomedica reported a net loss of $3.2 million, down from $6.1 million a year earlier. Gross margin was 61%, and cash, cash equivalents and available-for-sale securities totaled $40.9 million at September 30, 2026.